Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

July 30, 2026 08:30 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026

THE WOODLANDS, Texas, July 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its second quarter 2026 financial results...
July 27, 2026 08:30 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)

Study substantially exceeded enrollment target of 500 patients Topline results anticipated in Q1 2027 THE WOODLANDS, Texas, July 27, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc....
June 03, 2026 08:00 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions

THE WOODLANDS, Texas, June 03, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that it will present data from clinical studies of sotagliflozin in Type 1...
May 28, 2026 08:30 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference

THE WOODLANDS, Texas, May 28, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 2026 Jefferies...
May 12, 2026 08:30 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference

THE WOODLANDS, Texas, May 12, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the 4th Annual H.C....
May 07, 2026 07:30 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates

SONATA-HCM anticipated to be fully enrolled mid-2026 Resubmission of NDA for ZYNQUISTA® in type 1 diabetes anticipated mid-2026 with potential for approval this year Clinical development of LX9851...
May 04, 2026 16:05 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital

THE WOODLANDS, Texas, May 04, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) announced today that it has entered into a loan facility with Hercules Capital, Inc. (NYSE: HTGC)...
April 30, 2026 08:00 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026

THE WOODLANDS, Texas, April 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced the Company will release its first quarter 2026 financial results on Thursday,...
April 17, 2026 08:00 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting

Oral presentation highlights additional data from PROGRESS Phase 2b study of pilavapadin supporting selection of 10mg as optimal dose for Phase 3 development in DPNP New data on spasticity further...
March 24, 2026 08:00 ET | Source: Lexicon Pharmaceuticals, Inc.

Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo

THE WOODLANDS, Texas, March 24, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced three presentations of sotagliflozin clinical data during the American College...